Dosing & Uses
Dosing Forms & Strength
1-2 tablets PO q4-6hr PRN
Safetyand efficacy not established
Frequency Not Defined (common)
Tinnitus (high or chronic dose)
Repeated administration in patients with anemia, pulmonary, cardiac conditions, or renal disease
Gastrointestinal bleeding; particular caution in patients with history of GI bleed, alcoholism, or bleeding disorders
Avoid with active peptic ulcer disease, severe hepatic impairment, and severe renal impairment (ie, CrCl<10 mL/min)
Pregnancy & Lactation
Pregnancy category: D; avoid during pregnancy, particularly in third trimester because of risk for premature closure of the ductus arteriosus
Lactation: Excreted in breast milk; not recommended
Seek advice of health professional before using OTC drugs if pregnant or breastfeeding
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Magnesium salicylate: Nonsteroidal anti-inflammatory agent (NSAID) with analgesic and antipyretic properties.
Pamabrom: Weak diuretic action